NCARD Publications (2015 to now)

2021

Alves E, Taifour S, Dolcetti R, Chee J, Nowak AK, Gaudieri S, Blancafort P. 2021. Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. Molecular Therapy – Methods and Clinical Development. 21:592-606. https://doi.org/10.1016/j.omtm.2021.04.009
Charng J, Attia MS, Arunachalam S, Lam W-S, Creaney J, Muruganandan S, Read C, Millward M, Spiro J, Chakera A, Lee YCG, Nowak AK, Chen FK. 2021. Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1-3 tyrosine kinase inhibitor anticancer therapy. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.13940
Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å. 2021. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. Journal of Translational Medicine. 19(1):Article 232. https://doi.org/10.1186/s12967-021-02905-3
Philip J, Le Gautier R, Collins A, Nowak AK, Le B, Crawford GB, Rankin N, Krishnasamy M, Mitchell G, McLachlan SA, IJzerman M, Hudson R, Rischin D, Sousa TV, Sundararajan V. 2021. Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol. BMC Health Services Research. 21(1):Article 513. https://doi.org/10.1186/s12913-021-06476-3
Louw A, Lee YCG, Acott N, Creaney J, van Vliet C, Chai SM. 2021. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology. Cytopathology. https://doi.org/10.1111/cyt.13015
Creemers JHA, Lesterhuis WJ, Mehra N, Gerritsen WR, Figdor CG, de Vries IJM, Textor J. 2021. A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. Journal for ImmunoTherapy of Cancer . 9(5):Article e002032. https://doi.org/10.1136/jitc-2020-002032
Principe N, Kidman J, Lake RA, Lesterhuis WJ, Nowak AK, McDonnell AM, Chee J. 2021. Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?. Frontiers in Oncology. 11:Article 672747. https://doi.org/10.3389/fonc.2021.672747
Cook AM, McDonnell A, Millward MJ, Creaney J, Hasani A, McMullen M, Meniawy T, Robinson BWS, Lake RA, Nowak AK. 2021. A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2021.1882308
Fitzgerald DB, Popowicz ND, Joseph J, Butcher SC, Westcott M, Lim EM, Creaney J, Lee YCG. 2021. Trace element levels in pleural effusions. Health  Science Reports. 4(2):Article e262. https://doi.org/10.1002/hsr2.262
Popowicz N, Cheah HM, Gregory C, Miranda A, Dick IM, Lee YCG, Creaney J. 2021. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. PLoS One. 16(4):Article e0250628. https://doi.org/10.1371/journal.pone.0250628
Harris EJA, Lim KP, Moodley Y, Adler B, Sodhi-Berry N, Reid A, Murray CP, Franklin PJ, Musk AW, de Klerk NH, Brims FJH. 2021. Low dose CT detected interstitial lung abnormalities in a population with low asbestos exposure. American Journal of Industrial Medicine. https://doi.org/10.1002/ajim.23251
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. 2021. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 397(10272):375-386. https://doi.org/10.1016/S0140-6736(20)32714-8
Carey RN, Pfau JC, Fritzler MJ, Creaney J, de Klerk N, W (Bill) Musk A, Franklin P, Sodhi-Berry N, Brims F, Reid A. 2021. Autoantibodies and cancer among asbestos-exposed cohorts in Western Australia. Journal of Toxicology and Environmental Health – Part A: Current Issues. https://doi.org/10.1080/15287394.2021.1889424
Cheah HM, Fitzgerald D, Louw A, Creaney J, Lee YCG. 2021. Hyaluronic acid in viscous malignant mesothelioma pleural effusion. Respirology Case Reports. 9(1):Article e00694. https://doi.org/10.1002/rcr2.694
D’Alonzo RA, Gill S, Rowshanfarzad P, Keam S, MacKinnon KM, Cook AM, Ebert MA. 2021. In vivo noninvasive preclinical tumor hypoxia imaging methods: a review. International Journal of Radiation Biology. https://doi.org/10.1080/09553002.2021.1900943
Durber K, Halkett GKB, McMullen M, Nowak AK. 2021. Measuring financial toxicity in Australian cancer patients – Validation of the COmprehensive Score for financial Toxicity (FACT COST) measuring financial toxicity in Australian cancer patients. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13508
Fear V, Forbes C, Neeve S, Fisher S, Chee J, Waithman J, Ma S, Lake R, Nowak A, Creaney J, Brown M, Saunders C, Robinson B. 2021. Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. Cancer immunology, immunotherapy. https://doi.org/10.1007/s00262-021-02934-3
Jhala G, Selck C, Chee J, Kwong CTJ, Pappas EG, Thomas HE, Kay TWH, Krishnamurthy B. 2021. Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice. Frontiers in Immunology. 12:Article 645817. https://doi.org/10.3389/fimmu.2021.645817
Jhala G, Selck C, Chee J, Kwong CTJ, Pappas EG, Thomas HE, Kay TWH, Krishnamurthy B. 2021. Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice. Frontiers in Immunology. 12:Article 645817. https://doi.org/10.3389/fimmu.2021.645817
Lee YCG, Creaney J. 2021. Endomicroscopy of the pleura highlights challenges and limitations of pleuroscopy. Respirology. 26(2):138-139. https://doi.org/10.1111/resp.13982
Marcq E, Van Audenaerde JRM, De Waele J, Merlin C, Pauwels P, Van Meerbeeck JP, Fisher SA, Smits ELJ. 2021. The search for an interesting partner to combine with PD-L1 blockade in mesothelioma: Focus on TIM-3 and LAG-3. Cancers. 13(2):1-14. https://doi.org/10.3390/cancers13020282
Nowak AK. 2021. New and old treatments for malignant mesothelioma: not just immunotherapy. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(20)30516-6
Ye L, Creaney J, Redwood A, Robinson B. 2021. The Current Lung Cancer Neoantigen Landscape and Implications for Therapy. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2021.01.1624
Addala V, Sneddon S, Dick I, Fennell D, Pearson JV, Robinson B, Creaney J, Patch A-M, Waddell N. 2020. Dissecting tumour-immune interactions in mesothelioma for identifying responders to immune checkpoint blockade. Annals of Oncology. 31:S1453-S1453. https://doi.org/10.1016/j.annonc.2020.10.577

2020

Brims FJH, Kong K, Harris EJA, Sodhi-Berry N, Reid A, Murray CP, Franklin PJ, Musk AB, De Klerk NH. 2020. Pleural plaques and the risk of lung cancer in asbestos-exposed subjects. American Journal of Respiratory and Critical Care Medicine. 201(1):57-62. https://doi.org/10.1164/rccm.201901-0096OC
Cerciello F, Choi M, Sinicropi-Yao SL, Lomeo K, Amann JM, Felley-Bosco E, Stahel RA, Robinson B, Creaney J, Pass HI, Vitek O, Carbone DP. 2020. A targeted proteomics biomarker signature for the detection of malignant pleural mesothelioma from the blood.
Cerciello F, Choi M, Sinicropi-Yao SL, Lomeo K, Amann JM, Felley-Bosco E, Stahel RA, Robinson BWS, Creaney J, Pass HI, Vitek O, Carbone DP. 2020. Verification of a blood-based targeted proteomics signature for malignant pleural mesothelioma. Cancer Epidemiology Biomarkers and Prevention. 29(10):1973-1982. https://doi.org/10.1158/1055-9965.EPI-20-0543
Chee J, Wilson C, Buzzai A, Wylie B, Forbes CA, Booth M, Principe N, Foley B, Cruickshank MN, Waithman J. 2020. Impaired T cell proliferation by ex vivo BET-inhibition impedes adoptive immunotherapy in a murine melanoma model. Epigenetics. 15(1-2):1-11. https://doi.org/10.1080/15592294.2019.1656156
Fisher SA, Peddle-McIntyre CJ, Burton K, Newton RU, Marcq E, Lake RA, Nowak AK. 2020. Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model. BMC Research Notes. 13(1). https://doi.org/10.1186/s13104-020-05284-y
Hoon SN, Fyfe K, Peddle-Mcintyre CJ, Bowyer S, Hawkins F, Jeffery E, Chih HJ, Creaney J, Nowak A, Brims F. 2020. Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): Rationale and protocol. BMJ Open Respiratory Research. 7(1):Article e000551. https://doi.org/10.1136/bmjresp-2019-000551
Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, Wu D, Li X, Wu L, Sun J, He J, Robinson BWS, Zhu B. 2020. Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer. Advanced Science. 7(9):Article 1903410. https://doi.org/10.1002/advs.201903410
Keam S, Gill S, Ebert MA, Nowak AK, Cook AM. 2020. Enhancing the efficacy of immunotherapy using radiotherapy. Clinical and Translational Immunology. 9(9):Article e1169. https://doi.org/10.1002/cti2.1169
Kidman J, Principe N, Watson M, Lassmann T, Holt RA, Nowak AK, Lesterhuis WJ, Lake RA, Chee J. 2020. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. Frontiers in Immunology. 11:Article 587014. https://doi.org/10.3389/fimmu.2020.587014
Lam WS, Creaney J, Chen FK, Chin WL, Muruganandan S, Arunachalam S, Attia MS, Read C, Murray K, Millward M, Spiro J, Chakera A, Gary Lee YC, Nowak AK. 2020. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. Lung Cancer. 140:87-92. https://doi.org/10.1016/j.lungcan.2019.12.018
Louw A, Creaney J, Thomas A, Van Vliet C, Harvey NT, Wood BA, Mesbah Ardakani N. 2020. Histologically Diverse BAP1-Deficient Melanocytic Tumors in a Patient With BAP1 Tumor Predisposition Syndrome. The American Journal of Dermatopathology. 42(11):872-875. https://doi.org/10.1097/DAD.0000000000001719
Louw A, Sidhu C, Fitzgerald D, Creaney J, Chai SM, Lee YCG. 2020. Clump material within drainage chest tubes contain diagnostic information: A proof-of-concept case series. The European Respiratory Journal. 57(3). https://doi.org/10.1183/13993003.03248-2020
Louw A, Wallace C, Chai SM, Amanuel B, Wong DD. 2020. ALK positive malignant peritoneal mesothelioma mimicking inflammatory myofibroblastic tumour: a diagnostic pitfall. Pathology. 52(6):719-722. https://doi.org/10.1016/j.pathol.2020.06.016
MacMillan M, Roy B, McLaren S, Nowak AK, Thomas R, Lee YCG. 2020. Widespread pulmonary invasion by malignant pleural mesothelioma: an important diagnostic consideration. Respirology Case Reports. 8(9):Article e00675. https://doi.org/10.1002/rcr2.675
Mo L, Adler B, Green C, Brims FJH. 2020. Malignant mesothelioma presenting as a solitary perifissural nodule. Internal Medicine Journal. 50(12):1592-1594. https://doi.org/10.1111/imj.15120
Newton JC, O’Connor M, Saunders C, Moorin R, Ali S, Nowak AK, Halkett GKB. 2020. The role of psychosocial support in the experiences of people living with advanced cancer: A qualitative exploration of patients’ perspectives. Psycho-Oncology. https://doi.org/10.1002/pon.5569
Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Lang-Lazdunski L, Cree I, Rusch VW, Girard N, Galateau-Salle F. 2020. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology. 15(1):29-49. https://doi.org/10.1016/j.jtho.2019.08.2506
Nowak AK, Brosseau S, Cook A, Zalcman G. 2020. Antiangiogeneic Strategies in Mesothelioma. Frontiers in Oncology. 10:Article 126. https://doi.org/10.3389/fonc.2020.00126
Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BGM, Karikios DJ, John T, Kao SCH, Leslie C, Cook AM, Pavlakis N, Briscoe K, O’Byrne KJ, Karapetis CS, Lam WS, Langford A, Yip S, Stockler MR. 2020. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology. 21(9):1213-1223. https://doi.org/10.1016/S1470-2045(20)30462-9
Principe N, Kidman J, Goh S, Tilsed CM, Fisher SA, Fear VS, Forbes CA, Zemek RM, Chopra A, Watson M, Dick IM, Boon L, Holt RA, Lake RA, Nowak AK, Lesterhuis WJ, McDonnell AM, Chee J. 2020. Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. Frontiers in Immunology. 11:Article 584423. https://doi.org/10.3389/fimmu.2020.584423
Roshkovan L, Thompson JC, Katz SI, Deshpande C, Jenkins T, Nowak AK, Francis R, Dennie C, Fabre D, Singhal S, Galperin-Aizenberg M. 2020. Alveolar adenoma of the lung: Multidisciplinary case discussion and review of the literature. Journal of Thoracic Disease. 12(11):6847-6853. https://doi.org/10.21037/jtd-20-1831
Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak A, Fujimoto N, Peters S, Tsao A, Mansfield A, Popat S, Sun X, Padilla B, Aanur P, Daumont M, Bennett B, McKenna M, Baas P. 2020. First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. Annals of Oncology. 31:S1441-S1441. https://doi.org/10.1016/j.annonc.2020.10.603
Tsao AS, Baas P, Nowak A, Zalcman G, Fujimoto N, Peters S, Baudelet C, Aanur P, Osawa M, Tendolkar A, Feng Y, Sheng J. 2020. Evaluation of flat dosing for nivolumab (NIVO) plus ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743). Annals of Oncology. 31:S1445-S1445. https://doi.org/10.1016/j.annonc.2020.10.556
Ye L, Mesbah Ardakani N, Thomas C, Spilsbury K, Leslie C, Amanuel B, Millward M. 2020. Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. Pathology and Oncology Research. https://doi.org/10.1007/s12253-020-00833-z
Zemek RM, Chin WL, Nowak AK, Millward MJ, Lake RA, Lesterhuis WJ. 2020. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Frontiers in Immunology. 11:Article 223. https://doi.org/10.3389/fimmu.2020.00223
Zemek RM, Fear VS, Forbes C, de Jong E, Casey TH, Boon L, Lassmann T, Bosco A, Millward MJ, Nowak AK, Lake RA, Lesterhuis WJ. 2020. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nature Protocols. https://doi.org/10.1038/s41596-020-0299-3

 

2019

Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE. 2019. Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model. Biochemical and Biophysical Research Communications. 510(2):198-204. https://doi.org/10.1016/j.bbrc.2019.01.057
Armato SG, Francis RJ, Katz SI, Ak G, Opitz I, Gudmundsson E, Blyth KG, Gupta A. 2019. Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer. 130:108-114. https://doi.org/10.1016/j.lungcan.2018.11.033
Aston WJ, Hope DE, Cook AM, Boon L, Dick I, Nowak AK, Lake RA, Lesterhuis WJ. 2019. Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. OncoImmunology. https://doi.org/10.1080/2162402X.2019.1641390
Birnie KA, Prele CM, Musk AWB, de Klerk N, Lee YCG, Fitzgerald D, Allcock RJN, Thompson PJ, Creaney J, Badrian B, Mutsaers SE. 2019. MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions. Disease Markers. Article 8628612. https://doi.org/10.1155/2019/8628612
Brims F, Kong K, Harris E, Reid A, Murray C, Franklin P, Sodhi-Berry N, Musk A, de Klerk N. 2019. Presence of Pleural Plaques and/or Asbestosis and the Risk of Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 199.
Brims F, Popowicz N, Rosenstengel A, Hart J, Yogendran A, Read CA, Lee F, Shrestha R, Franke A, Lewis JR, Kay I, Waterer G, Lee YCG. 2019. Bacteriology and clinical outcomes of patients with culture-positive pleural infection in Western Australia: A 6-year analysis. Respirology. 24(2):171-178. https://doi.org/10.1111/resp.13395
Chin WL, Zemek RM, Lesterhuis WJ, Lassmann T. 2019. Functional genomics in cancer immunotherapy: Computational approaches for biomarker and drug discovery. Molecular Systems Design and Engineering. 4(4):689-700. https://doi.org/10.1039/c9me00029a
Fear V, Cook A, Fisher S. 2019. The Future of Mesothelioma Research: Basic Science Research. In Caring for Patients with Mesothelioma: Principles and Guidelines. Switzerland: Springer Nature. pp. 203-227. https://doi.org/10.1007/978-3-319-96244-3_18
Fear VS, Forbes CA, Chee J, Ma S, Neeve S, Celliers L, Fisher SA, Dick I, Creaney J, Robinson BWS. 2019. Neo-antigen specific T cell responses indicate the presence of metastases before imaging. Scientific Reports. 9(1). https://doi.org/10.1038/s41598-019-51317-3
Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedres S, Nolan L, Kindler H, Aerts JGJV. 2019. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. Journal of Clinical Oncology. 37(10):790-798. https://doi.org/10.1200/JCO.2018.79.0543
Fennell DA, Taylor P, Gilligan D, Nakano T, Scherpereel A, Pavlakis N, Van Meerbeeck JP, Aerts JGJV, Nowak AK, Kindler H, Baas P. 2019. Reply to K. Masuda et al. Journal of Clinical Oncology. 37(25):2294-2295. https://doi.org/10.1200/JCO.19.01208
Ferjancic P, Ebert MA, Nowak AK, Francis RJ, Jeraj R. 2019. Test-Retest Repeatability of 18F-FET PET in Small Volumes. Medical Physics. 46(6):E398-E398.
Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. 2019. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Journal of Thoracic Oncology. 14(10):1718-1731. https://doi.org/10.1016/j.jtho.2019.08.012
Harris E, Franklin P, Sodhi-Berry N, Olsen N, Musk A, Reid A, De Klerk N, Brims F. 2019. Metformin may reduce mesothelioma and lung cancer incidence among asbestos-exposed. Respirology. 24:163-163.
Harris EJA, Kao S, McCaughan B, Nakano T, Kondo N, Hyland R, Nowak AK, de Klerk NH, Brims FJH. 2019. Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery. Journal of Thoracic Oncology. 14(2):288-293. https://doi.org/10.1016/j.jtho.2018.10.005
Harris EJA, Musk AW, DeKlerk N, Brims FJH. 2019. Comment on: “Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos”. Lung Cancer. 136:148-149. https://doi.org/10.1016/j.lungcan.2019.04.019
Jeffery E, Lee YCG, Newton RU, Lyons-Wall P, McVeigh J, Nowak AK, Cheah HM, Nguyen B, Fitzgerald DB, Creaney J, Straker L, Peddle-McIntyre CJ. 2019. Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life. European Journal of Clinical Nutrition. 73(10):1412-1421. https://doi.org/10.1038/s41430-019-0418-9
Kamiya H, Peters S, Sodhi-Berry N, Reid A, Gordon L, de Klerk N, Brims F, Musk AW, Franklin P. 2019. Validation of an Asbestos Job-Exposure Matrix (AsbJEM) in Australia: Exposure-Response Relationships for Malignant Mesothelioma. Annals of Work Exposures and Health. 63(7):719-728. https://doi.org/10.1093/annweh/wxz038
Lam W, Nowak A, Chen F, Muruganandan S, Arunachalam S, Chin M, Millward M, Read C, Murray K, Creaney J, Lee YCG. 2019. Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study. Journal of Thoracic Oncology. 14(10):S342-S342. https://doi.org/10.1016/j.jtho.2019.08.691
Lépine PA, Thomas R, Nguyen S, Lacasse Y, Cheah HM, Creaney J, Muruganandan S, Martel S, Lee YCG, Delage A. 2019. Simplified criteria using pleural fluid cholesterol and lactate dehydrogenase to distinguish between exudative and transudative pleural effusions. Respiration. 98(1):48-54. https://doi.org/10.1159/000496396
Louw A, Badiei A, Creaney J, Chai MS, Lee YCG. 2019. Advances in pathological diagnosis of mesothelioma: what pulmonologists should know. Current Opinion in Pulmonary Medicine. 25(4):354-361. https://doi.org/10.1097/MCP.0000000000000578
Ma S, Chee J, Fear VS, Forbes CA, Boon L, Dick IM, Robinson BWS, Creaney J. 2019. Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. OncoImmunology. Article 1684714. https://doi.org/10.1080/2162402X.2019.1684714
Mendoza TR, Williams LA, Keating KN, Siegel J, Elbi C, Nowak AK, Hassan R, Cuffel B, Cleeland CS. 2019. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Journal of Patient-Reported Outcomes. 3(1):Article 34. https://doi.org/10.1186/s41687-019-0122-5
Musk AWB, Reid A, Olsen N, Hobbs M, Armstrong B, Franklin P, Hui J, Layman L, Merler E, Brims F, Alfonso H, Shilkin K, Sodhi-Berry N, de Klerk N. 2019. The Wittenoom legacy. International Journal of Epidemiology. Article dyz204. https://doi.org/10.1093/ije/dyz204
Nowak AK, Forde PM. 2019. Immunotherapy trials in mesothelioma — promising results, but don’t stop here. Nature Reviews Clinical Oncology. 16:726-728. https://doi.org/10.1038/s41571-019-0291-4
Nowak AK, McDonnell A, Cook A. 2019. Immune checkpoint inhibition for the treatment of mesothelioma. Expert Opinion on Biological Therapy. 19(7). https://doi.org/10.1080/14712598.2019.1606209
Reid A, Franklin P, Berry G, Peters S, Sodhi-Berry N, Brims F, Musk AW, de Klerk NH. 2019. Response to: ‘Are children more vulnerable to mesothelioma than adults? A comparison of mesothelioma risk among children and adults exposed non-occupationally to blue asbestos at Wittenoom’ by Reid et al Response. Occupational and Environmental Medicine. 76(5):356-356. https://doi.org/10.1136/oemed-2019-105740
Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sorensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS. 2019. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine. 7(7):569-580. https://doi.org/10.1016/S2213-2600(19)30139-0
Sidhu C, Louw A, Brims F, Creaney J, Lee YCG. 2019. Malignant Pleural Mesothelioma: an Update for Pulmonologists. Current Pulmonology Reports. 8(2):40-49. https://doi.org/10.1007/s13665-019-0224-9
Sneddon S, Rive CM, Ma S, Dick IM, Allcock RJN, Brown SD, Holt RA, Watson M, Leary S, Lee YCG, Robinson BWS, Creaney J. 2019. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. OncoImmunology. Article 1684713. https://doi.org/10.1080/2162402X.2019.1684713
Tsao A, Nakano T, Nowak AK, Popat S, Scagliotti GV, Heymach J. 2019. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in Oncology. 46(2):145-154. https://doi.org/10.1053/j.seminoncol.2019.06.001
Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. 2019. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. Journal of Thoracic Oncology. 14(10):1704-1717. https://doi.org/10.1016/j.jtho.2019.06.020
Wylie B, Chee J, Forbes CA, Booth M, Stone SR, Buzzai A, Abad A, Foley B, Cruickshank MN, Waithman J. 2019. Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens. OncoImmunology. https://doi.org/10.1080/2162402X.2019.1609874
Ye L, Leslie C, Jacques A, Ardakani NM, Amanuel B, Millward M. 2019. Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. Modern Pathology. 32(4):524-531. https://doi.org/10.1038/s41379-018-0173-9
Ye L, Ma S, Robinson BW, Creaney J. 2019. Immunotherapy strategies for mesothelioma–the role of tumor specific neoantigens in a new era of precision medicine. Expert Review of Respiratory Medicine. 13(2):181-192. https://doi.org/10.1080/17476348.2019.1563488
Zemek R, de Jong E, Chin M, Schuster I, Fear V, Casey T, Forbes C, Dart S, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, O Muiri D, Degli-Esposti M, Millward M, Nowak A, Lassmann T, Bosco A, Lake R, Lesterhuis W. 2019. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Science Translational Medicine. 11(501):Article eaav7816. https://doi.org/10.1126/scitranslmed.aav7816

 

2018

Armato SG, Nowak AK. 2018. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). Journal of Thoracic Oncology. 13(7):1012-1021. https://doi.org/10.1016/j.jtho.2018.04.034
Badiei A, Chan KP, Lee YC, Waterer GW. 2018. Corticosteroids in lung and pleural infections. Current Pulmonology Reports. 7(1):19. https://doi.org/10.1007/s13665-018-0197-0
Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, Harrison RN, Mustafa RA, Bishop LJ, Ahmed L, West A, Holme J, Evison M, Munavvar M, Sivasothy P, Herre J, Cooper D, Roberts M, Guhan A, Hooper C, Walters J, Saba TS, Chakrabarti B, Gunatilake S, Psallidas I, Walker SP, Bibby AC, Smith S, Stadon LJ, Zahan-Evans NJ, Lee YCG, Harvey JE, Rahman NM, Miller RF, Maskell NA. 2018. Outpatient talc administration by indwelling pleural catheter for malignant effusion. New England Journal of Medicine. 378(14):1313-1322. https://doi.org/10.1056/NEJMoa1716883
Chan KP, Fitzgerald D, Lee YC. 2018. Emerging concepts in pleural infection. Current Opinion in Pulmonary Medicine. 24(4):367-373. https://doi.org/10.1097/MCP.0000000000000487
Chee J, Watson MW, Chopra A, Nguyen B, Cook AM, Creaney J, Lesterhuis WJ, Robinson BW, Gary Lee YC, Nowak AK, Lake RA, McDonnell AM. 2018. Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Research Notes. 11(1):Article 864. https://doi.org/10.1186/s13104-018-3953-x
Fear V, Tilsed CM, Chee HEJ, Forbes C, Casey T, Solin J, Lansley S, Lesterhuis W, Dick I, Nowak A, Robinson B, Lake R, Fisher S. 2018. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncolmmunology. Article e1494111. https://doi.org/10.1080/2162402X.2018.1494111
Gardner JK, Cornwall SMJ, Musk AW, Alvarez J, Mamotte CDS, Jackaman C, Nowak AK, Nelson DJ. 2018. Elderly dendritic cells respond to LPS/IFN-gamma and CD40L stimulation despite incomplete maturation. PLoS One. 13(4):Article 0195313. https://doi.org/10.1371/journal.pone.0195313
Harris E, Murray C, Franklin P, Sodhi-Berry N, Reid A, Olsen N, Hall D, De Klerk N, Musk A, Brims F. 2018. LUNG CANCER SCREENING IN THE WESTERN AUSTRALIAN ASBESTOS REVIEW PROGRAM. Respirology. 23:38-38.
Humphries T, Robinson C, Giardina T, Nowak A, Robinson S, Iacopetta B, Stewart C, Meniawy T, Kumarasinghe P, Wood B, Thomas C, De Boer B, Leung Y, Robbins P, Van Hazel G, Ferguson T, Raftopoulos S, Millward M, Amanuel B. 2018. Clinical implementation of personalised medicine for six high priority WA cancers. Asia-Pacific Journal of Clinical Oncology. 14:157-158.
Kamiya H, De Klerk N, Peters S, Sodhi-Berry N, Olsen N, Brims F, Musk AWB, Franklin P. 2018. Validation of an asbestos job-exposure matrix: Exposure-response relationships for malignant mesothelioma. Respirology. 23:202-202.
Lansley S, Della Vergiliana JV, Creaney J, Lee Y. 2018. Bacteria as Novel Anti-Mesothelioma Agents. Journal of Thoracic Oncology. 13(10):S750-S750. https://doi.org/10.1016/j.jtho.2018.08.1275
Leong SL, Davis HE, Lee YC. 2018. Malignant Pleural Mesothelioma. Shah PL, Herth FJF, Lee YCG, Criner GC, editors. In Essentials of Clinical Pulmonology. 1 ed. USA: CRC Press.
Lin RT, Soeberg MJ, Chien LC, Fisher S, Takala J, Lemen R, Driscoll T, Takahashi K. 2018. Bibliometric analysis of gaps in research on asbestos-related diseases: Declining emphasis on public health over 26 years. BMJ Open. 8(7):Article e022806. https://doi.org/10.1136/bmjopen-2018-022806
Marini KD, Croucher DR, McCloy RA, Vaghjiani V, Gonzalez-Rajal A, Hastings JF, Chin V, Szczepny A, Kostyrko K, Marquez C, Samantha W, Jayasekara N, Alamgeer M, Boolell V, Han JZR, Waugh T, Lee HC, Oakes SR, Kumar B, Harrison CA, Hedger MP, Lorensuhewa N, Kita B, Barrow R, Robinson BW, De Kretser DM, Wu J, Ganju V, Alejandro Sweet-Cordero E, Burgess A, Martelotto LG, Rossello FJ, Cain JE, Neil Watkins D. 2018. Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine. 10(451):Article eaat3504. https://doi.org/10.1126/scitranslmed.aat3504
MC3 Working Group, The Cancer Genome Atlas Research Network. 2018. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems. 6(3):271-281.e7. https://doi.org/10.1016/j.cels.2018.03.002
McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T. 2018. Progress in the Management of Malignant Pleural Mesothelioma in 2017. Journal of Thoracic Oncology. 13(5):606-623. https://doi.org/10.1016/j.jtho.2018.02.021
Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors and Pathology Committees. 2018. Eighth edition staging of thoracic malignancies: Implications for the reporting pathologist. Archives of Pathology and Laboratory Medicine. 142(5):645-661. https://doi.org/10.5858/arpa.2017-0245-RA
Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O’Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T. 2018. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(11):1784-1791. https://doi.org/10.1016/j.jtho.2018.08.007
Musk A, Reid A, Olsen N, Hobbs M, Armstrong B, Franklin P, Hui J, Layman L, Brims F, Alfonso H, Shilkin K, Sodhi-Berry N, De Klerk N. 2018. THE WITTENOOM LEGACY. Respirology. 23(Suppl:1 (SI)):205-205.
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. 2018. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal of Thoracic Oncology. 13(9):1269-1283. https://doi.org/10.1016/j.jtho.2018.06.011
Nowak A. 2018. Impact of Tumor Volume on Outcome: What Are the Limitations?. Journal of Thoracic Oncology. 13(10):S293-S294. https://doi.org/10.1016/j.jtho.2018.08.186
Patch AM, Nones K, Kazakoff SH, Newell F, Wood S, Leonard C, Holmes O, Xu Q, Addala V, Creaney J, Robinson BW, Fu S, Geng C, Li T, Zhang W, Liang X, Rao J, Wang J, Tian M, Zhao Y, Teng F, Gou H, Yang B, Jiang H, Mu F, Pearson JV, Waddell N. 2018. Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. PLoS One. 13(1):Article e0190264. https://doi.org/10.1371/journal.pone.0190264
Popowicz ND, Fitzgerald D, Joseph J, Lim EM, Cheah HM, Butcher S, Creaney J, Lee YCG. 2018. Trace element concentrations in human pleural effusions. Abstract from The Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science, Adelaide, Australia.
Popowicz ND, Gregory CL, Miranda AK, Cheah HM, Dick IM, Lee YCG, Creaney J. 2018. Prognostic significance of the neutrophil to lymphocyte ratio in pleural fluid.
Reid A, Franklin P, Berry G, Peters S, Sodhi-Berry N, Brims F, Musk AW, De Klerk NH. 2018. Are children more vulnerable to mesothelioma than adults? A comparison of mesothelioma risk among children and adults exposed non-occupationally to blue asbestos at Wittenoom. Occupational and Environmental Medicine. 75(12):898-903. https://doi.org/10.1136/oemed-2018-105108
Reid A, Franklin P, de Klerk N, Creaney J, Brims F, Musk B, Pfau J. 2018. Autoimmune antibodies and asbestos exposure: Evidence from Wittenoom, Western Australia. American Journal of Industrial Medicine. 61(7):615-620. https://doi.org/10.1002/ajim.22863
Sneddon SA, Dick IM, Lee YC, Musk AW, Allcock RJ, Waddell N, Patch A-M, Pearson JV, Holt RA, Robinson BW, Creaney J. 2018. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer. 119:64-70. https://doi.org/10.1016/j.lungcan.2018.03.009
TCGA Research Network. 2018. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discovery. 8(12):1549-1565. https://doi.org/10.1158/2159-8290.CD-18-0804
The Cancer Genome Atlas Network. 2018. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 173(2):291-304.e6. https://doi.org/10.1016/j.cell.2018.03.022
The Cancer Genome Atlas Network. 2018. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems. 6(3):282-300.e2. https://doi.org/10.1016/j.cels.2018.03.003
The Cancer Genome Atlas Research Network, Creaney J. 2018. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 173(2):305-320.e10. https://doi.org/10.1016/j.cell.2018.03.033
The Cancer Genome Atlas Research Network. 2018. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 33(4):690-705.e9. https://doi.org/10.1016/j.ccell.2018.03.014
The Cancer Genome Atlas Research Network. 2018. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell. 173(2):386-399.e12. https://doi.org/10.1016/j.cell.2018.03.027
The Cancer Genome Atlas Research Network. 2018. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems. 7(4):422-437.e7. https://doi.org/10.1016/j.cels.2018.08.010
The Cancer Genome Atlas Research Network. 2018. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 173(2):400-416.e11. https://doi.org/10.1016/j.cell.2018.02.052
The Cancer Genome Atlas Research Network. 2018. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. 33(4):721-735.e8. https://doi.org/10.1016/j.ccell.2018.03.010
The Cancer Genome Atlas Research Network. 2018. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell. 34(2):211-224.e6. https://doi.org/10.1016/j.ccell.2018.07.001
The Cancer Genome Atlas Research Network. 2018. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Reports. 25(5):1304-1317.e5. https://doi.org/10.1016/j.celrep.2018.10.001
The Cancer Genome Atlas Research Network. 2018. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 33(4):676-689.e3. https://doi.org/10.1016/j.ccell.2018.03.007
The Cancer Genome Atlas Research Network. 2018. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports. 23(1):239-254.e6. https://doi.org/10.1016/j.celrep.2018.03.076
The Cancer Genome Atlas Research Network. 2018. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports. 23(1):194-212.e6. https://doi.org/10.1016/j.celrep.2018.03.063
The Cancer Genome Atlas Research Network. 2018. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell. 33(4):706-720.e9. https://doi.org/10.1016/j.ccell.2018.03.006
The Cancer Genome Atlas Research Network. 2018. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports. 23(1):172-180.e3. https://doi.org/10.1016/j.celrep.2018.03.046
The Cancer Genome Atlas Research Network. 2018. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 173(2):338-354.e15. https://doi.org/10.1016/j.cell.2018.03.034
The Cancer Genome Atlas Research Network. 2018. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173(2):321-337.e10. https://doi.org/10.1016/j.cell.2018.03.035
The Cancer Genome Atlas Research Network. 2018. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports. 23(1):297-312.e12. https://doi.org/10.1016/j.celrep.2018.03.064
The Cancer Genome Atlas Research Network. 2018. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 173(2):355-370.e14. https://doi.org/10.1016/j.cell.2018.03.039
The Cancer Genome Atlas Research Network. 2018. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports. 23(1):282-296.e4. https://doi.org/10.1016/j.celrep.2018.01.088
The Cancer Genome Atlas Research Network. 2018. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports. 23(1):181-193.e7. https://doi.org/10.1016/j.celrep.2018.03.086
The Cancer Genome Atlas Research Network. 2018. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports. 23(1):270-281.e3. https://doi.org/10.1016/j.celrep.2018.03.052
The Cancer Genome Atlas Research Network. 2018. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23(1):313-326.e5. https://doi.org/10.1016/j.celrep.2018.03.075
The Cancer Genome Atlas Research Network. 2018. The Immune Landscape of Cancer. Immunity. 48(4):812-830.e14. https://doi.org/10.1016/j.immuni.2018.03.023
The Fusion Analysis Working Group, The Cancer Genome Atlas Research Network. 2018. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports. 23(1):227-238.e3. https://doi.org/10.1016/j.celrep.2018.03.050
The MC3 Working Group, The Cancer Genome Atlas Research Network. 2018. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 173(2):371-385.e18. https://doi.org/10.1016/j.cell.2018.02.060
Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. 2018. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology. 13(11):1655-1667. https://doi.org/10.1016/j.jtho.2018.08.2036

 

2017

Arunachalam S, Lam W-S, Nowak A, Creaney J, Millward M, Muruganandan S, Read C, Lee G, Chen F. 2017. SEROUS RETINAL DETACHMENT DUE TO FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR IN MALIGNANT PLEURAL MESOTHELIOMA. Clinical & Experimental Ophthalmology. 45:135-135.
Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. 2017. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 17(1):Article 684. https://doi.org/10.1186/s12885-017-3677-7
Brims F, Guntilake S, Lawrie I, Marshall L, Fogg C, Maskell N, Forbes K, Rahman N, Morris S, Gerry S, Chauhan A. 2017. RESPECT-MESO: AN INTERNATIONAL MULTICENTRE NON-BLINDED RANDOMIZED CONTROLLED TRIAL TO ASSESS THE IMPACT OF REGULAR EARLY SPECIALIST PALLIATIVE CARE IN MALIGNANT PLEURAL MESOTHELIOMA. Respirology. 22:71-71.
Cerciello F, Choi M, Lomeo K, Amann JM, Felley-Bosco E, Stahel RA, Robinson B, Creaney J, Pass HI, Vitek O, Carbone DP. 2017. Multiplexed targeted proteomics signature for serum diagnostic of malignant pleural mesothelioma. Annals of Oncology. 28.
Cheah HM, Lansley SM, Varano della Vergiliana JF, Tan AL, Thomas R, Leong SL, Creaney J, Lee YCG. 2017. Malignant pleural fluid from mesothelioma has potent biological activities. Respirology. 22(1):192-199. https://doi.org/10.1111/resp.12874
Chee J, Robinson BWS, Holt RA, Creaney J. 2017. Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies. Chest. 151(4):891-897. https://doi.org/10.1016/j.chest.2016.10.007
Creaney J, Dick IM, Leon JS, Robinson BWS. 2017. A proteomic analysis of the malignant mesothelioma secretome using iTRAQ. Cancer Genomics and Proteomics. 14(2):103-117. https://doi.org/10.21873/cgp.20023
Creaney J, Robinson BWS. 2017. Malignant Mesothelioma Biomarkers From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment. Chest. 152(1):143-149. https://doi.org/10.1016/j.chest.2016.12.004
Fisher S, Aston W, Chee HEJ, Khong A, Cleaver A, Solin J, Ma S, Lesterhuis W, Dick I, Holt R, Creaney J, Boon L, Robinson B, Lake R. 2017. Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immunity Inflammation and Disease. 5(1):16-28. https://doi.org/10.1002/iid3.136
Grosso F, Steele N, Novello S, Nowak A, Popat S, Greillier L, von Wangenheim U, Morsli N, Barrueco J, Scagliotti G. 2017. Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial. Annals of Oncology. 28.
Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sorensen JB, Socinski MA, von Wangenheim U, Loembe AB, Barrueco J, Morsli N, Scagliotti G. 2017. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. 35(31):3591-3600. https://doi.org/10.1200/JCO.2017.72.9012
Harris E, Kao S, Nakano T, Kondo N, Nowak A, Brims F. 2017. PREDICTION MODELING USING ROUTINE CLINICAL PARAMETERS TO STRATIFY SURVIVAL IN MESOTHELIOMA PATIENTS UNDERGOING SURGERY. Respirology. 22:67-68.
Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, Haas ND, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ. 2017. Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget. 8(33):54434-54443. https://doi.org/10.18632/oncotarget.17661
Ho J, McWilliams A, Emery J, Saunders C, Reid C, Robinson S, Brims F. 2017. Integrated care for resected early stage lung cancer: Innovations and exploring patient needs. BMJ Open Respiratory Research. 4(1):Article e000175. https://doi.org/10.1136/bmjresp-2016-000175
Hoy RF, Brims F. 2017. Occupational lung diseases in Australia. Medical Journal of Australia. 207(10):443-448. https://doi.org/10.5694/mja17.00601
Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, Taeger D, Lehnert M, Kollmeier J, Bauer T, Musk AW, Robinson BWS, Brüning T, Creaney J. 2017. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 17(1):Article 386. https://doi.org/10.1186/s12885-017-3375-5
Lam W-S, Lee YCG, Creaney J, Muruganandan S, Millward M, Read C, Nowak A. 2017. A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma – Trial in Progress. Journal of Thoracic Oncology. 12(1):S1087-S1087.
Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. 2017. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nature Reviews Drug Discovery. 16(4):264–272. https://doi.org/10.1038/nrd.2016.233
Lim KP, Brims F, Mcwilliams A, Tammemzgi M, Berg C, Marshall H, Stone E, Manser R, Canfell K, Connelly L, Yee J, Fong K, Lam S. 2017. PROTOCOL FOR THE INTERNATIONAL LUNG SCREEN TRIAL (ILST): A COHORT STUDY TO DEFINE LDCT SCREENING SELECTION CRITERIA AND VALIDATE THE PANCAN NODULE MANAGEMENT ALGORITHM. Respirology. 22:66-66.
Lim KP, Manners D, Adler B, Melsom S, Harris E, Brims F, Mcwilliams A. 2017. UPDATE FROM THE LUNGSCREEN WA PROJECT – A FEASABILITY STUDY OF LOW-DOSE CT LUNG CANCER SCREENING OF HIGH-RISK EVER SMOKERS IN AUSTRALIA. Respirology. 22:64-65.
Lim KP, Manners D, Adler B, Melsom S, Harris E, Brims FJ, McWilliams AM. 2017. THE LUNGSCREEN WA PROJECT: RESULTS FROM A PROSPECTIVE LDCT SCREENING PROGRAMME OF HIGH-RISK SMOKERS. Respiratory Medicine. 132:278-278.
Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL. 2017. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology. 18(9):1261-1273. https://doi.org/10.1016/S1470-2045(17)30446-1
Manners D, Wong P, Murray C, Teh J, Kwok YJ, de Klerk N, Alfonso H, Franklin P, Reid A, Musk AWB, Brims FJH. 2017. Correlation of ultra-low dose chest CT findings with physiologic measures of asbestosis. European Radiology. 27(8):3485-3490. https://doi.org/10.1007/s00330-016-4722-7
McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, Platell CF. 2017. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget. 8(12):19803-19813. https://doi.org/10.18632/oncotarget.15048
McDonnell AM, Cook A, Robinson BWS, Lake RA, Nowak AK. 2017. Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. BMC Cancer. 17:Article 417. https://doi.org/10.1186/s12885-017-3403-5
McIntyre CJ, Jeffery E, Lee YCG, Nowak AK, Nguyen B, Newton RU. 2017. Feasibility and Preliminary Efficacy of a 6-Week Exercise Intervention in Patients with Malignant Pleural Disease. Asia-Pacific Journal of Clinical Oncology. 13:218-219.
Muruganandan S, Alfonso H, Franklin P, Shilkin K, Segal A, Olsen N, Reid A, De Klerk N, Musk AW, Brims F. 2017. Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma. British Journal of Cancer. 116(6):703-708. https://doi.org/10.1038/bjc.2017.20
Musk ABW, de Klerk N, Brims FJ. 2017. Mesothelioma in australia: A review. Medical Journal of Australia. 207(10):449-452. https://doi.org/10.5694/mja17.00397
Novello S, Nowak AK, Grosso F, Steele N, Popat S, Greillier L, John T, Leighl NB, Reck M, Pavlakis N, Sorensen JB, Planchard D, Ceresoli GL, Hughes B, Mazieres J, Socinski MA, von Wangenheim U, Barrueco J, Morsli N, Scagliotti G. 2017. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) plus pemetrexed/cisplatin (PEM/CIS) vs placebo (P) plus PEM/CIS in chemo-naive patients (pts) with malignant pleural mesothelioma (MPM). Annals of Oncology. 28.
Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S. 2017. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer. 18(5):589-593. https://doi.org/10.1016/j.cllc.2017.03.010
Sneddon S, Patch AM, Dick IM, Kazakoff SH, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J. 2017. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer. 17(1):Article 396. https://doi.org/10.1186/s12885-017-3382-6
Sodhi-Berry N, De Klerk N, Franklin P, Brims F, Peters S, Olsen N, Musk A. 2017. 0402 Does lung cancer incidence and mortality differ with the type of asbestos fibre? : evidence from Western Australia. Occupational and Environmental Medicine. 74(S1):A126. https://doi.org/10.1136/oemed-2017-104636.330
Weber M, Yap S, Goldsbury D, Manners D, Tammemagi M, Marshall H, Brims F, McWilliams A, Fong K, Kang YJ, Caruana M, Banks E, Canfell K. 2017. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCOm2012 risk prediction tool. International Journal of Cancer. 141(2):242-253. https://doi.org/10.1002/ijc.30673

 

2016

Armato SG, Blyth KG, Keating JJ, Katz S, Tsim S, Coolen J, Gudmundsson E, Opitz I, Nowak AK. 2016. Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. Lung Cancer. 101:48-58. https://doi.org/10.1016/j.lungcan.2016.09.003
Azzopardi M, Lee YC. 2016. Pleural Effusion Management in Malignant Pleural Mesothelioma. Mineo TC, editor. In Malignant Pleural Mesothelioma: Present Status and Future Directions. 1st ed. USA: Betham. pp. 285-303. https://doi.org/10.2174/97816810819461160101
Azzopardi M, Thomas R, Muruganandan S, Lam DCL, Garske LA, Kwan BCH, Rashid Ali MRS, Nguyen PT, Yap E, Horwood FC, Ritchie AJ, Bint M, Tobin CL, Shrestha R, Piccolo F, De Chaneet CC, Creaney J, Newton RU, Hendrie D, Murray K, Read CA, Feller-Kopman D, Maskell NA, Lee YCG. 2016. Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: A multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. BMJ Open. 6(7):Article e011480. https://doi.org/10.1136/bmjopen-2016-011480
Bintcliffe OJ, Lee GYC, Rahman NM, Maskell NA. 2016. The management of benign non-infective pleural effusions. European Respiratory Review. 25(141):303-316. https://doi.org/10.1183/16000617.0026-2016
Brims F, Meniawy T, Duffus I, De Fonseka D, Segal A, Creaney J, Maskell N, Lake R, De Klerk N, Nowak A. 2016. A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis. Journal of Thoracic Oncology. 11(4):573-582. https://doi.org/10.1016/j.jtho.2015.12.108
Brims FJ, McWilliams A, Fong K. 2016. Lung cancer screening in Australia: Progress or procrastination?: There is progress internationally with lung cancer screening but far slower headway in Australia. Medical Journal of Australia. 204(1):4-4.e1. https://doi.org/10.5694/mja15.01109
Cook A, McDonnell A, Lake R, Nowak A. 2016. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. OncoImmunology. 5(3):Article e1066062. https://doi.org/10.1080/2162402X.2015.1066062
Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. 2016. Chemotherapy and immunotherapy: Mapping the road ahead. Current Opinion in Immunology. 39:23-29. https://doi.org/10.1016/j.coi.2015.12.003
Cornwall SMJ, Wikstrom M, Musk AW, Alvarez J, Nowak AK, Nelson DJ. 2016. Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes. OncoImmunology. 5(2). https://doi.org/10.1080/2162402X.2015.1082028
Creaney J, Dick I, Musk AW, Olsen NJ, Robinson BWS. 2016. Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. Biomarkers. 21(6):551-561. https://doi.org/10.3109/1354750X.2016.1160429
Creaney J, Lee GCG. 2016. Diagnoses (not diagnosis) of pleural effusion: Time to consider concurrent etiologies. Annals of the American Thoracic Society. 13(7):1003-1004. https://doi.org/10.1513/AnnalsATS.201604-320ED
Francis RJ, Nowak AK. 2016. Radiology: Nuclear Imaging. Light RW, Lee YCG, editors. In Textbook of Pleural Diseases (3rd Edition). 3rd ed. CRC Press. pp. 234-243.
Franklin P, Alfonso H, Reid A, Olsen N, Shilkin K, Brims F, de Klerk N, Musk AW. 2016. Asbestos exposure and histological subtype of malignant mesothelioma. Occupational and Environmental Medicine. 73(11):749-752. https://doi.org/10.1136/oemed-2016-103721
Franklin P, Reid A, Olsen N, Peters S, De Klerk N, Brims F, Threlfall T, Murray R, Musk A. 2016. Incidence of malignant mesothelioma in Aboriginal people in Western Australia. Australian and New Zealand Journal of Public Health. 40(4):383-387. https://doi.org/10.1111/1753-6405.12542
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A, Bolejack V, Ball D, Beer DG, Beyruti R, Detterbeck F, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Huang J, Kennedy C, Kim J, Kim YT, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom EM, Van Meerbeeck J, Nakano T, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier JP, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas CF, Travis W, Tsao MS, Turrisi A, Vansteenkiste J, Watanabe H, Wu YL, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso PL, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Abad Cavaco F, Ansótegui Barrera E, Abal Arca J, Parente Lamelas I, Arnau Obrer A, Guijarro Jorge R, Bascom GK, Blanco Orozco AI, González Castro M, Blum MG, Chimondeguy D, Cvijanovic V, Defranchi S, De Olaiz Navarro B, Escobar Campuzano I, Macía Vidueira I, Fernández Araujo E, Andreo García F, Fong KM, Francisco Corral G, Cerezo González S, Freixinet Gilart J, García Arangüena L, García Barajas S, Girard P, Goksel T. 2016. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. Journal of Thoracic Oncology. 11(1):39-51. https://doi.org/10.1016/j.jtho.2015.09.009
Greening DW, Ji H, Chen M, Robinson BWS, Dick IM, Creaney J, Simpson RJ. 2016. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. Scientific Reports. 6:Article 32643 . https://doi.org/10.1038/srep32643
Kondola S, Manners D, Nowak A. 2016. Malignant pleural mesothelioma: an update on diagnosis and treatment options. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE. 10(3):275-288. https://doi.org/10.1177/1753465816628800
Lansley SM, Pedersen B, Robinson C, Searles RG, Sterrett G, Van Bruggen I, Lake RA, Mutsaers SE, Prele C. 2016. A subset of malignant mesothelioma tumors retain osteogenic potential. Scientific Reports. 6:Article 36349. https://doi.org/10.1038/srep36349
McDonnell AM. 2016. T cell phenotype and receptor expression in pleural effusions associated with malignant mesothelioma: Abstracts of ICI 2016 International Congress of Immunology, 21-26 August 2016, Melbourne, Australia. European Journal Immunology. 46(S1). https://doi.org/10.1002/eji.201670200
Meniawy T, Lake R, Mcdonnell A, Millward M, Nowak A. 2016. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer. 93:9-16. https://doi.org/10.1016/j.lungcan.2015.12.006
Morré DJ, Hostetler B, Taggart DJ, Morré DM, Musk AW, Robinson BWS, Creaney J. 2016. ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clinical Proteomics. 13(1). https://doi.org/10.1186/s12014-016-9103-3
Murray CP, Wong PM, Teh J, De Klerk N, Rosenow T, Alfonso H, Reid A, Franklin P, Musk A, Brims F. 2016. Ultra low dose CT screen-detected non-malignant incidental findings in the Western Australian Asbestos Review Programme. Respirology. 21(8):1419-1424. https://doi.org/10.1111/resp.12826
Musk A, Gordon L, Alfonso H, Reid A, Olsen N, Mina R, Franklin P, Brims F, Hui J, De Klerk N. 2016. MALIGNANT MESOTHELIOMA IN SUBJECTS WITH NO KNOWN EXPOSURE TO ASBESTOS: A CASE-CONTROL STUDY. Respirology. 21:178-178.
Musk AWBWB, Nowak AK, De Klerk NH. 2016. Asbestos exposure: Challenges for Australian clinicians. Medical Journal of Australia. 204(2):48-48.e1. https://doi.org/10.5694/mja15.01072
Nowak A, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, De Perrot M, Rusch VW. 2016. The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. Journal of Thoracic Oncology. 11(12):2089-2099. https://doi.org/10.1016/j.jtho.2016.08.147
Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, Van Meerbeeck JP, Nowak A, Rusch VW. 2016. The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. Journal of Thoracic Oncology. 11(12):2082-2088. https://doi.org/10.1016/j.jtho.2016.09.123
Popowicz ND, Gregory CL, Cheah HM, Lee YC, Creaney J. 2016. Prognostic Significance Of Neutrophil To Lymphocyte Ratio In Pleural Fluid And Blood Of Patients With Malignant Mesothelioma: ATS 2016, Vol 193. Abstract from American Thoracic Society International Conference, .
Psallidas I, Kalomenidis I, Porcel JM, Robinson B, Stathopoulos GT. 2016. Malignant pleural effusion: From bench to bedside. European Respiratory Review. 25(140):189-198. https://doi.org/10.1183/16000617.0019-2016
Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW. 2016. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology. 11(12):2100-2111. https://doi.org/10.1016/j.jtho.2016.09.121
Robles AI, Olsen KS, Tsui DWT, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD. 2016. Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: Innovation and implementation, June 16th and 17th 2016, Trondheim, Norway. Journal of Translational Medicine. 14(1):Article 295. https://doi.org/10.1186/s12967-016-1059-6
Rusch VW, Chansky K, Kindler HL, Nowak A, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, Mccaughan BC, Nakano T, Ruffini E, Van Meerbeeck JP, Yoshimura M. 2016. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology. 11(12):2112-2119. https://doi.org/10.1016/j.jtho.2016.09.124
Stathopoulos GT, Lee YC, Robinson BW. 2016. Experimental Models: Pleural Diseases. Light RW, Lee YCG, editors. In Textbook of Pleural Diseases. 3rd ed. Taylor & Francis. pp. 125-144.
Steven A, Fisher SA, Robinson BW. 2016. Immunotherapy for lung cancer. Respirology. 21(5):821-833. https://doi.org/10.1111/resp.12789
Thomas R, Cheah H, Creaney J, Turlach B, Lee G. 2016. Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. Chest. 149(6):1494-1500. https://doi.org/10.1016/j.chest.2016.01.001
Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, Goo JM, MacMahon H, Naidich D, Nicholson AG, Powell CA, Prokop M, Rami-Porta R, Rusch V, Van Schil P, Yatabe Y, Goldstraw P, Ball D, Beer D, Beyruti R, Bolejack V, Chansky K, Crowley J, Eberhardt WEE, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim YT, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom EM, Van Meerbeeck J, Mitchell A, Nakano T, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Saijo N, Sculier JP, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas CF, Tsao MS, Turrisi A, Vansteenkiste J, Watanabe H, Wu YL, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso PL, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E. 2016. The IASLC lung cancer staging project: Proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. Journal of Thoracic Oncology. 11(8):1204-1223. https://doi.org/10.1016/j.jtho.2016.03.025

 

2015

Armato III SG, Coolen J, Nowak A, Robinson C, Gill RR, Straus C, Khanwalkar A. 2015. Imaging in pleural mesothelioma: A review of the 12th International Mesothelioma Interest Group. Lung Cancer. 90(2):148-154. https://doi.org/10.1016/j.lungcan.2015.07.011
Birnie KA, Yip YY, Ng DCH, Kirschner MB, Reid G, Prêle C, Musk A, Lee G, Thompson P, Mutsaers S, Badrian B. 2015. Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma. Molecular Cancer Research. 13(7):1106-1118. https://doi.org/10.1158/1541-7786.MCR-14-0442
Cook A, Khong A, Nowak AK, Lake RA. 2015. Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. Lung Cancer Management. 4(5):249-259. https://doi.org/10.2217/lmt.15.23
Creaney J, Dick IM, Robinson BW. 2015. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Current Opinion in Pulmonary Medicine. 21(4):352-356. https://doi.org/10.1097/MCP.0000000000000167
Creaney J, Ma S, Sneddon SA, Tourigny M, Dick I, Leon J, Khong A, Fisher S, Lake R, Lesterhuis W, Nowak A, Leary S, Watson MW, Robinson B. 2015. Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. OncoImmunology. 4(7):1-7. https://doi.org/10.1080/2162402X.2015.1011492
Creaney J, Robinson BWS. 2015. Author’s response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax. 70(4):374-375. https://doi.org/10.1136/thoraxjnl-2014-206564
Francis R, Segard T, Morandeau L, Lee G, Millward M, Segal A, Nowak A. 2015. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer. 90(1):55-60. https://doi.org/10.1016/j.lungcan.2015.07.015
Hjerpe A, Ascoli V, Bedrossian C, Boon M, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael C, Onder S, Segal A, Vielh P. 2015. Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. CytoJournal. 12(26):Article 170726. https://doi.org/10.4103/1742-6413.170726
Hjerpe A, Ascoli V, Bedrossian CWM, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael CW, Önder S, Segal A, Vie P. 2015. Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication. Cytopathology. 26(3):142-156. https://doi.org/10.1111/cyt.12250
Hjerpe A, Ascoli V, Bedrossian CWM, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, Firat P, Kamei T, Kobayashi T, Michael CW, Önder S, Segal A, Vielh P. 2015. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Diagnostic Cytopathology. 43(7):563-576. https://doi.org/10.1002/dc.23271
Johnson C, Saunders C, Phillips M, Emery J, Nowak A, Overheu K, Ward AM, Joske DJL. 2015. Randomized Controlled Trial of Shared Care for Patients With Cancer Involving General Practitioners and Cancer Specialists. Journal of Oncology Practice. 11(5):349-355. https://doi.org/10.1200/JOP.2014.001569
Leong SL, Lee G, Robinson B, Creaney J. 2015. Role of Mesothelin Measurement in Patients With Cytology-Negative Pleural Effusion Undergoing Medical Thoracoscopy. PLEURA. N/A:1-7. https://doi.org/10.1177/2373997515579639
Leong SL, Zainudin R, Kazan-Allen L, Robinson B. 2015. Asbestos in Asia. Respirology. 20(4):548-555. https://doi.org/10.1111/resp.12517
Lesterhuis W, Rinaldi C, Jones A, Rozali E, Dick I, Khong A, Boon L, Robinson B, Nowak A, Bosco A, Lake R. 2015. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. Scientific Reports. 5:1-11. https://doi.org/10.1038/srep12298
Lim CB, Prêle C, Baltic S, Arthur P, Creaney J, Neil Watkins D, Thompson P, Mutsaers S. 2015. Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis. Oncotarget. 6(3):1519-1530. https://doi.org/10.18632/oncotarget.2729
Mccoy M, Hemmings C, Miller T, Austin SJ, Bulsara MK, Zeps N, Nowak A, Lake R, Platell C. 2015. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. British Journal of Cancer. 113(12):1677-1686. https://doi.org/10.1038/bjc.2015.427
Mcdonnell A, Lesterhuis W, Khong A, Nowak A, Lake R, Currie A, Robinson B. 2015. Restoration of defective cross-presentation in tumors by gemcitabine. OncoImmunology. 4(5):e1005501. https://doi.org/10.1080/2162402X.2015.1005501
Mcdonnell A, Lesterhuis W, Khong A, Nowak A, Lake R, Currie AJ, Robinson B. 2015. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. European Journal of Immunology. 45(1):49-59. https://doi.org/10.1002/eji.201444722
Meniawy T, Lake R, McDonnell A, Millward M, Nowak A. 2015. Up regulation of PD-L1 on peripheral blood CD3+T cells predicts poor prognosis in patients with non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) inhibitors. European Journal of Cancer. 51(S3):S47-S47. https://doi.org/10.1016/S0959-8049(16)30148-4, https://doi.org/10.1016/S0959-8049(16)30148-4
Nowak A, Cook A, Mcdonnell A, Millward M, Creaney J, Francis R, Hasani A, Segal A, Musk A, Turlach B, Mccoy M, Robinson B, Lake R. 2015. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Annals of Oncology. 26(12):2483-2490. https://doi.org/10.1093/annonc/mdv387
Nowak AK, Lesterhuis-Vasbinder D, Lesterhuis WJ. 2015. New directions in mesothelioma treatment. Lung Cancer Management. 4(6):299-307. https://doi.org/10.2217/lmt.15.32
Robinson C, Dick I, Wise M, Holloway A, Diyagama D, Robinson B, Creaney J, Lake R. 2015. Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. BMC Cancer. 15:Article 983. https://doi.org/10.1186/s12885-015-1953-y
Sneddon S, Leon J, Dick I, Cadby G, Olsen N, Brims F, Allcock R, Moses E, Melton P, De Klerk N, Musk A, Robinson B, Creaney J. 2015. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene. 563(1):103-105. https://doi.org/10.1016/j.gene.2015.03.031
Menu